Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis

COGNITION THERAPEUTICS INC

FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.
Company believes it has a path forward for zervimesine (CT1812) to treat dementia with Lewy bodies patients with psychosis.
Formal FDA minutes expected in June 2026.
Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage company developing neurodegenerative disorder treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.